IQVIA (NYSE:IQV) Rating Increased to Buy at Wall Street Zen

IQVIA (NYSE:IQV) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Sunday.

Several other research analysts also recently commented on IQV. Robert W. Baird set a $258.00 target price on IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. JPMorgan Chase & Co. raised their price objective on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Truist Financial upped their target price on IQVIA from $265.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, January 8th. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the stock from $195.00 to $235.00 in a research report on Thursday, October 9th. Finally, Stifel Nicolaus increased their price objective on shares of IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $251.06.

IQVIA Stock Down 1.6%

NYSE:IQV opened at $235.20 on Friday. IQVIA has a one year low of $134.65 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The company has a market cap of $40.05 billion, a PE ratio of 32.26, a P/E/G ratio of 2.39 and a beta of 1.36. The firm’s 50 day simple moving average is $229.10 and its 200 day simple moving average is $205.90.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, research analysts anticipate that IQVIA will post 10.84 earnings per share for the current year.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

A number of large investors have recently modified their holdings of IQV. Ameliora Wealth Management Ltd. acquired a new position in IQVIA during the fourth quarter worth $25,000. Physician Wealth Advisors Inc. increased its position in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after acquiring an additional 134 shares in the last quarter. Westside Investment Management Inc. raised its holdings in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC bought a new position in IQVIA in the 3rd quarter valued at about $30,000. Finally, Atlantic Union Bankshares Corp acquired a new position in IQVIA during the 3rd quarter valued at about $36,000. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.